{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:38:08Z","timestamp":1793731088701,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02289-w","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T03:12:24Z","timestamp":1662952344000},"page":"5176-5190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-1296","authenticated-orcid":false,"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Zagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena H.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"2289_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137.","journal-title":"J Headache Pain"},{"key":"2289_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322.","journal-title":"Cephalalgia"},{"key":"2289_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945\u201355.","journal-title":"Curr Med Res Opin"},{"key":"2289_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther. 2022;11:205\u201322.","journal-title":"Neurol Ther"},{"key":"2289_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20:68.","journal-title":"J Headache Pain"},{"key":"2289_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111.","journal-title":"J Headache Pain"},{"key":"2289_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22:29.","journal-title":"J Headache Pain"},{"key":"2289_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ncn3.12322","volume":"7","author":"N Araki","year":"2019","unstructured":"Araki N, Takeshima T, Ando N, et al. Clinical practice guideline for chronic headache 2013. Neurol Clin Neurosci. 2019;7:231\u201359.","journal-title":"Neurol Clin Neurosci"},{"key":"2289_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12883-020-01848-4","volume":"20","author":"K Hirata","year":"2020","unstructured":"Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme. BMC Neurol. 2020;20:274.","journal-title":"BMC Neurol"},{"key":"2289_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1526-4610.2009.01595.x","volume":"50","author":"ME Bigal","year":"2010","unstructured":"Bigal ME, Golden W, Buse D, Chen YT, Lipton RB. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010;50:256\u201363.","journal-title":"Headache"},{"key":"2289_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1\u201318.","journal-title":"Headache"},{"key":"2289_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"2289_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646\u201357.","journal-title":"Headache"},{"key":"2289_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-2982.2006.01275.x","volume":"27","author":"S Silberstein","year":"2007","unstructured":"Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27:220\u20139.","journal-title":"Cephalalgia"},{"key":"2289_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"R Lipton","year":"2008","unstructured":"Lipton R, Bigal M, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148\u201358.","journal-title":"Ann Neurol"},{"key":"2289_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688\u201395.","journal-title":"Neurology"},{"key":"2289_CR17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2169\/naika.108.1024","volume":"108","author":"The Japanese Council on Cerebro-Cardiovascular Disease","year":"2019","unstructured":"The Japanese Council on Cerebro-Cardiovascular Disease. Comprehensive risk management chart for cerebro-cardiovascular disease 2019. Nihon Naika Gakkai Zasshi. 2019;108:1024\u201374.","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"2289_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62:122\u201340.","journal-title":"Headache"},{"key":"2289_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.1468-2982.2007.01389.x","volume":"27","author":"N Imai","year":"2007","unstructured":"Imai N, Kitamura E, Konishi T, Suzuki Y, Serizawa M, Okabe T. Clinical features of probable medication-overuse headache: a retrospective study in Japan. Cephalalgia. 2007;27:1020\u20133.","journal-title":"Cephalalgia"},{"key":"2289_CR20","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1007\/s10072-021-05831-w","volume":"43","author":"M Katsuki","year":"2022","unstructured":"Katsuki M, Yamagishi C, Matsumori Y, et al. Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city\u2014Itoigawa study. Neurol Sci. 2022;43:3811\u201322.","journal-title":"Neurol Sci"},{"key":"2289_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40122-020-00223-y","volume":"10","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Unmet needs in Japanese patients who report insufficient efficacy with triptans for acute treatment of migraine: retrospective analysis of real-world data. Pain Ther. 2021;10:415\u201332.","journal-title":"Pain Ther"},{"key":"2289_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21:41.","journal-title":"J Headache Pain"},{"key":"2289_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2078302","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Komori M, Tanji Y, Ozeki A, Hirata K. Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opin Drug Saf. 2022. https:\/\/doi.org\/10.1080\/14740338.2022.2078302.","journal-title":"Expert Opin Drug Saf"},{"key":"2289_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/head.12962","volume":"57","author":"DC Buse","year":"2017","unstructured":"Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57:31\u201344.","journal-title":"Headache"},{"key":"2289_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/head.13179","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57:1507\u201321.","journal-title":"Headache"},{"key":"2289_CR26","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB, et al. Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health. 2020;11:2150132720963680.","journal-title":"J Prim Care Community Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02289-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T20:49:30Z","timestamp":1701031770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02289-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02289-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}